DPYD and dihydropyrimidine dehydrogenase deficiency: Initial dose reduction of at least 50% is proposed in patients heterozygous for DPYD*2A, DPYD*13, and c.2846A>T who are considered to have intermediate or partial DPD enzyme activity, while a choice of alternative drug is strongly recommended for patients with complete DPD deficiency [11].